COST-EFFECTIVENESS ANALYSIS OF INNOVATIVE THERAPY FOR PATIENTS WITH NEWLY DIAGNOSED HORMONE-SENSITIVE METASTATIC PROSTATE CANCER

被引：0
|
作者：
Pelloux-Prayer, R. [1 ]
Schiele, P. [1 ]
Oudard, S. [2 ]
Gravis, G. [3 ]
Kleinclauss, F. [1 ]
Crehange, G. [4 ]
Hennequin, C. [5 ]
Morgans, A. [6 ]
Geoffrois, L. [7 ]
Limat, S. [1 ]
Thiery-Vuillemin, A. [1 ]
Nerich, V [1 ]
机构：
[1] Univ Hosp Besancon, Besancon, France
[2] Georges Pompidou Hosp, Paris, France
[3] Inst Paoli Calmettes, Marseille, France
[4] Inst Curie, Paris, France
[5] Hosp St Louis, Paris, France
[6] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[7] Inst Cancerol Lorraine Alexis Vautrin, Vandoeuvre Les Nancy, France
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSC134
引用
收藏
页码：S113 / S113
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness Analysis of Innovative Therapy for Patients with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer
    Pelloux-Prayer, Remi
    Schiele, Philomene
    Oudard, Stephane
    Gravis, Gwenaelle
    Kleinclauss, Francois
    Crehange, Gilles
    Hennequin, Christophe
    Morgans, Alicia K.
    Geoffrois, Lionel
    Limat, Samuel
    Thiery-Vuillemin, Antoine
    Nerich, Virginie
    CLINICAL GENITOURINARY CANCER, 2021, 19 (05) : E326 - E333
  • [2] Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer
    Barbier, Michaela C.
    Tomonaga, Yuki
    Menges, Dominik
    Yebyo, Henock G.
    Haile, Sarah R.
    Puhan, Milo A.
    Schwenkglenks, Matthias
    PLOS ONE, 2022, 17 (11):
  • [3] A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer
    Sung, W. W.
    Choi, H. C.
    Luk, P. H.
    So, T. H.
    ANNALS OF ONCOLOGY, 2020, 31 : S1326 - S1326
  • [4] A Cost-Effectiveness Analysis of Systemic Therapy for Metastatic Hormone-Sensitive Prostate Cancer
    Sung, Winnie W. Y.
    Choi, Horace C. W.
    Luk, Peter H. Y.
    So, Tsz Him
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [5] A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer
    Sathianathen, Niranjan J.
    Alarid-Escudero, Fernando
    Kuntz, Karen M.
    Lawrentschuk, Nathan
    Bolton, Damien M.
    Murphy, Declan G.
    Kim, Simon P.
    Konety, Badrinath R.
    EUROPEAN UROLOGY ONCOLOGY, 2019, 2 (06): : 649 - 655
  • [6] Cost-Effectiveness Analysis of Systemic Therapy for Intensification of Treatment in Metastatic Hormone-Sensitive Prostate Cancer in India
    Nidhi Gupta
    Dharna Gupta
    Kiran Gopal Vaska
    Shankar Prinja
    Applied Health Economics and Health Policy, 2024, 22 : 415 - 426
  • [7] Cost-Effectiveness Analysis of Systemic Therapy for Intensification of Treatment in Metastatic Hormone-Sensitive Prostate Cancer in India
    Gupta, Nidhi
    Gupta, Dharna
    Vaska, Kiran Gopal
    Prinja, Shankar
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2024, 22 (03) : 415 - 426
  • [8] Cost-effectiveness analysis of rezvilutamide versus bicalutamide in the treatment of metastatic hormone-sensitive prostate cancer
    Ding, Haiying
    Li, Shujing
    Xu, Xinglu
    Xu, Weiben
    He, Chaoneng
    Xin, Wenxiu
    Zhan, ZhaJun
    Fang, Luo
    BMJ OPEN, 2024, 14 (07): : 1 - 6
  • [9] Cost-effectiveness of docetaxel in high-volume hormone-sensitive metastatic prostate cancer
    Beca, Jaclyn
    Majeed, Habeeb
    Chan, Kelvin K. W.
    Hotte, Sebastian J.
    Loblaw, Andrew
    Hoch, Jeffrey S.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2019, 13 (12): : 396 - 403
  • [10] COST-EFFECTIVENESS OF SYSTEMIC TREATMENT INTENSIFICATION IN MEN WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
    Sathianathen, Niranjan
    Lawrentschuk, Nathan
    Azad, Arun
    Konety, Badrinath
    Murphy, Declan
    JOURNAL OF UROLOGY, 2023, 209 : E492 - E492
12345